Antimicrobial resistance, virulence factors and genetic lineages of hospital-onset methicillin-resistant Staphylococcus aureus isolates detected in a hospital in Zaragoza

Enfermedades infecciosas y microbiología clínica
María González-DomínguezFrancisco Javier Castillo

Abstract

MRSA population dynamics is undergoing significant changes, and for this reason it is important to know which clones are circulating in our nosocomial environment. A total of 118 MRSA isolates were collected from clinical samples from patients with previous hospital or healthcare contact (named as hospital-onset MRSA (HO-MRSA)) during a one year period. Susceptibility testing was performed by disk diffusion and microdilution. The presence of resistance genes and virulence factors were tested by PCR. All isolates were typed by SCCmec, spa and agr typing. PFGE and MLST were applied to a selection of them. Eighty-three HO-MRSA isolates (70.3%) were resistant to any antibiotic included in the macrolide-lincosamide-streptogramin B group. Among these isolates, the M phenotype was the most frequent (73.5%). One hundred and seven of HO-MRSA isolates (90.7%) showed aminoglycoside resistance. The combination aac(6')-Ie-aph(2″)-Ia+ant(4')-Ia genes was the most frequent (22.4%). Tetracycline resistance rates in HO-MRSA isolates were low (3.4%), although a high level of mupirocin resistance was observed (25.4%). Most of the HO-MRSA isolates (approximately 90%) showed SCCmec type IVc and agr type II. Fifteen unrelated pulsotypes were identif...Continue Reading

References

Dec 22, 1999·The Journal of Laryngology and Otology·M F Tungekar
Oct 9, 2004·Journal of Clinical Microbiology·Eduardo Pérez-RothSebastián Méndez-Alvarez
Mar 30, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·R H DeurenbergE E Stobberingh
Mar 30, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·O CuevasUNKNOWN Spanish Group for the Study of Staphylococcus
Jan 15, 2008·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A ManzurJ Ariza
Jan 27, 2009·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J A OtterG L French
Jan 20, 2010·PLoS Medicine·Hajo GrundmannUNKNOWN European Staphylococcal Reference Laboratory Working Group
Jan 23, 2010·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·C PotelS Perez
Apr 3, 2010·British Medical Bulletin·Fiona J Cooke, Nicholas M Brown
Aug 10, 2010·Nursing for Women's Health·Janis R Guilbeau, Lisa P Broussard
Jan 12, 2011·Antimicrobial Agents and Chemotherapy·Jérôme RobertUNKNOWN ONERBA (Observatoire National de l'Epidémiologie de Résistance Bactérienne aux Antibiotiques)
Jan 11, 2012·International Journal of Antimicrobial Agents·Stefania StefaniFiona M Mackenzie
Oct 12, 2012·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Carmen LozanoCarmen Torres
Nov 28, 2012·International Journal of Medical Microbiology : IJMM·María González-DomínguezFrancisco Javier Castillo

❮ Previous
Next ❯

Citations

May 3, 2016·Diagnostic Microbiology and Infectious Disease·María González-DomínguezFrancisco Javier Castillo
Feb 13, 2018·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Elina JokinenJaana Syrjänen
Aug 24, 2019·Journal of Global Antimicrobial Resistance·Masoud DadashiMehdi Goudarzi

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.